default author photo

Christopher Nicholas Hurt

Cardiff University - Centre for Trials Research

SCHOLARLY PAPERS

2

DOWNLOADS

157

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

A Multi-Centre Randomised Phase II Trial of Early Pet-Ct Directed Switch to Carboplatin and Paclitaxel Based Definitive Chemoradiotherapy in Patients with Oesophageal Cancer Who Have a Poor Early Response to Induction Cisplatin and Capecitabine

Number of pages: 33 Posted: 07 Mar 2023
Government of the United Kingdom - Oxford Cancer Centre, Cardiff University - Centre for Trials Research, Cardiff University - Centre for Trials Research, Cardiff University - Centre for Trials Research, Cardiff University - Wales Research and Diagnostic Positron Emission Tomography Centre (PETIC), Cardiff University - Centre for Trials Research, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, University of Southampton - Southampton Clinical Trials Unit, Swansea Bay University Health Board - South West Wales Cancer Centre, University of Cambridge - Department of Oncology, Cardiff University - Centre for Trials Research, University of Oxford - MRC Oxford Institute for Radiation Oncology, Cardiff University - Centre for Trials Research, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, Government of the United Kingdom - Hull University Teaching Hospitals NHS Trust, Cardiff University - Centre for Trials Research, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, Cardiff University - School of Engineering, University College London - Department of Medical Physics and Biomedical Engineering and Velindre Cancer Centre
Downloads 79 (809,932)

Abstract:

Loading...

oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, chemoradiotherapy

2.

Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study

Number of pages: 38 Posted: 29 Jan 2024
Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, University of Oxford, University of Oxford, University of Cambridge - Department of Oncology, University College London - UCL Cancer Institute, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, University of Oxford - Nuffield Department of Primary Care Health Sciences, University of Oxford, University of Oxford, Velindre Cancer Centre, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Imperial College London - Hammersmith Hospital, Department of Cancer Medicine, University of Cambridge, NHS Foundation Trust - Norfolk and Norwich University Hospital, Government of the United Kingdom - Hull University Teaching Hospitals NHS Trust, Coventry University - Coventry University Hospital, Cardiff University - Centre for Trials Research, University of Leeds - Institute of Medical Research, University of Oxford - MRC Oxford Institute for Radiation Oncology, University College London - Department of Medical Physics and Biomedical Engineering and University of Cambridge
Downloads 78 (823,616)

Abstract:

Loading...

Pancreatic cancer, Chemoradiotherapy, Nelfinavir, Dose escalation, Survival, Outcomes, Toxicity, Health-related quality of life